IRVINE, Calif., Endologix, developer and marketer of innovative treatments for aortic disorders, announced today that the first U.S. commercial implant of the Company's AFX ® 2 Bifurcated Endograft ...

IRVINE, Calif.--(BUSINESS WIRE)--Endologix LLC, a privately held global medical device company, dedicated to improving patients’ lives with innovative interventional treatments for vascular disease, ...

For the second time this year, the US Food and Drug Administration has issued a safety communication to healthcare professionals regarding risk of Type III endoleaks associated with Endologix AFX ...

The US Food and Drug Administration (FDA) has issued an update to its January 2022 safety communication on the use of Endologix AFX endovascular grafts to treat patients with abdominal aortic aneurysm ...

Following discussions with the Food and Drug Administration, Endologix, Inc. (NASDAQ:ELGX) has issued updating information to physicians concerning the AFX Endovascular AAA System. The letter ...

Endologix seems to be taking a proactive stance to nip an AFX manufacturing glitch in the bud, but analysts wonder if the company's portfolio is just too broad. The company expects to share more ...

Please provide your email address to receive an email when new articles are posted on . Endologix announced that the FDA has approved a bifurcated endograft system for the treatment of abdominal ...

IRVINE, Calif.--(BUSINESS WIRE)--Endologix LLC, a privately held global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, has ...

Jan 17 (Reuters) - Endologix Inc By Reuters January 17, 20173:34 PM UTCUpdated ago Jan 17 (Reuters) - Endologix Inc * ENDOLOGIX RESUMES SHIPMENTS OF ALL SIZES OF AFX 2 ENDOVASCULAR AAA SYSTEMS ...

The AFX2 System integrates anatomical fixation into aortic endografts with an advanced delivery system to treat patients with abdominal aortic aneurysm (AAA). IRVINE, Calif.--(BUSINESS ...